Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trials
ReumatologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Lupus science & medicine
- Publicado em
- 8 abr 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trials
Andrea Doria, Ronald van Vollenhoven, Eric Morand, Marta Mosca, Jonatan Nåtman, Miina Waratani, Jacob Knagenhjelm, Catharina Lindholm, Danuta Kielar
Descritores MeSH
- Lupus Erythematosus, Systemic
- Antibodies, Monoclonal, Humanized
- Humans
- Immunosuppressive Agents
- Adult
- Middle Aged
- Remission Induction
- Severity of Illness Index
- Treatment Outcome
- Male
Veja também
Estudos relacionados
- Long-term efficacy and safety of belimumab in children with systemic lupus erythematosus: a meta-analysis of real-world data
- Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study
- Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials
- Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better Health-Related Quality of Life